Form 4 for RGNX REGENXBIO Inc.
Accepted 2026-05-13 17:18:54 ET · period of report 2026-05-11 · accession 0001700659-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-13 17:18 | 2026-05-11 | RGNX | PAKOLA STEVE | Chief Medical Off | S - Sale | $11.02 | -15.3K | 232.6K | -6% | -$168.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | S | D | 15,309 | $11.02 | 232,617 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan. (F2) This transaction was executed in multiple trades at prices ranging from $11.00 to $11.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |